RATIONALE: Invasive aspergillosis is a severe fungal infection afflicting immunocompromised patients, particularly patients with neutrophil defects. CCR6, a beta-chemokine receptor, mediates migration of dendritic cells (DCs) and several lymphocyte subsets to sites of epithelial inflammation, but its role in infections has not been examined extensively. OBJECTIVES: To test the hypothesis that CCR6-mediated leukocyte recruitment is necessary for effective host defense in neutropenic hosts with invasive pulmonary aspergillosis. METHODS: Neutropenic wild-type mice and mice with targeted deletion of CCR6 were infected with Aspergillus fumigatus. The host responses to the infection were compared in vivo and leukocyte responses to the fungus were examined in vitro. MEASUREMENTS AND MAIN RESULTS: In the context of infection, immature myeloid DCs were the major population of CCR6-expressing cells in the lungs. As compared with wild-type animals, CCR6-deficient mice developed a more severe infection when challenged with A. fumigatus conidia, as documented by a higher mortality rate and greater lung fungal burden. This was associated with reduced accumulation of DCs in the lungs. CCR6-deficient and wild-type DCs did not differ in their phagocytosis of conidia, cytokine response, or maturation in vitro. In adoptive transfer experiments, however, DCs from CCR6-deficient donors showed lesser accumulation in the lungs of infected mice as compared with wild-type cells, and transfer of wild-type, but not CCR6-deficient, DCs resulted in attenuated severity of infection in CCR6-deficient recipients. CONCLUSIONS: Taken together, these results implicate CCR6-mediated DC influx into the lung in the initial host defense in invasive aspergillosis.
RATIONALE: Invasive aspergillosis is a severe fungal infection afflicting immunocompromised patients, particularly patients with neutrophil defects. CCR6, a beta-chemokine receptor, mediates migration of dendritic cells (DCs) and several lymphocyte subsets to sites of epithelial inflammation, but its role in infections has not been examined extensively. OBJECTIVES: To test the hypothesis that CCR6-mediated leukocyte recruitment is necessary for effective host defense in neutropenic hosts with invasive pulmonary aspergillosis. METHODS:Neutropenic wild-type mice and mice with targeted deletion of CCR6 were infected with Aspergillus fumigatus. The host responses to the infection were compared in vivo and leukocyte responses to the fungus were examined in vitro. MEASUREMENTS AND MAIN RESULTS: In the context of infection, immature myeloid DCs were the major population of CCR6-expressing cells in the lungs. As compared with wild-type animals, CCR6-deficient mice developed a more severe infection when challenged with A. fumigatus conidia, as documented by a higher mortality rate and greater lung fungal burden. This was associated with reduced accumulation of DCs in the lungs. CCR6-deficient and wild-type DCs did not differ in their phagocytosis of conidia, cytokine response, or maturation in vitro. In adoptive transfer experiments, however, DCs from CCR6-deficient donors showed lesser accumulation in the lungs of infected mice as compared with wild-type cells, and transfer of wild-type, but not CCR6-deficient, DCs resulted in attenuated severity of infection in CCR6-deficient recipients. CONCLUSIONS: Taken together, these results implicate CCR6-mediated DC influx into the lung in the initial host defense in invasive aspergillosis.
Authors: K Hieshima; T Imai; G Opdenakker; J Van Damme; J Kusuda; H Tei; Y Sakaki; K Takatsuki; R Miura; O Yoshie; H Nomiyama Journal: J Biol Chem Date: 1997-02-28 Impact factor: 5.157
Authors: R Hromas; P W Gray; D Chantry; R Godiska; M Krathwohl; K Fife; G I Bell; J Takeda; S Aronica; M Gordon; S Cooper; H E Broxmeyer; M J Klemsz Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: A M Milik; V A Buechner-Maxwell; J Sonstein; S Kim; G D Seitzman; T F Beals; J L Curtis Journal: J Clin Invest Date: 1997-03-01 Impact factor: 14.808
Authors: Diego Serrano-Gómez; Angeles Domínguez-Soto; Julio Ancochea; José A Jimenez-Heffernan; Juan Antonio Leal; Angel L Corbí Journal: J Immunol Date: 2004-11-01 Impact factor: 5.422
Authors: E Cenci; A Mencacci; C Fè d'Ostiani; G Del Sero; P Mosci; C Montagnoli; A Bacci; L Romani Journal: J Infect Dis Date: 1998-12 Impact factor: 5.226
Authors: C A Power; D J Church; A Meyer; S Alouani; A E Proudfoot; I Clark-Lewis; S Sozzani; A Mantovani; T N Wells Journal: J Exp Med Date: 1997-09-15 Impact factor: 14.307
Authors: D R Greaves; W Wang; D J Dairaghi; M C Dieu; B Saint-Vis; K Franz-Bacon; D Rossi; C Caux; T McClanahan; S Gordon; A Zlotnik; T J Schall Journal: J Exp Med Date: 1997-09-15 Impact factor: 14.307
Authors: I Fugier-Vivier; C Servet-Delprat; P Rivailler; M C Rissoan; Y J Liu; C Rabourdin-Combe Journal: J Exp Med Date: 1997-09-15 Impact factor: 14.307
Authors: Stacy J Park; Marie D Burdick; William K Brix; Mark H Stoler; David S Askew; Robert M Strieter; Borna Mehrad Journal: J Immunol Date: 2010-10-06 Impact factor: 5.422
Authors: John J Osterholzer; Gwo-Hsiao Chen; Michal A Olszewski; Jeffrey L Curtis; Gary B Huffnagle; Galen B Toews Journal: J Immunol Date: 2009-12-15 Impact factor: 5.422